rilpivirine + tenofovir + emtricitabine

Home»rilpivirine + tenofovir + emtricitabine

EVIPLERA combines Truvada, a fixed-dose combination of two nucleoside/nucleotide reverse transcriptase inhibitors (tenofovir disoproxil fumarate 300mg and emtricitabine 200mg) and a non-nucleoside reverse transcriptase inhibitor (rilpivirine 25mg).

EVIPLERA is a once-daily single-tablet regimen for the treatment of HIV-1 infection in antiretroviral treatment-naïve adults with a pre-treatment viral load less than or equal to 100,000 HIV-1 RNA copies/mL. It is recommended that EVIPLERA be taken with a meal.

Approval of EVIPLERA was supported by 48-week data from two Phase III double-blind, active controlled, randomised studies (ECHO and THRIVE) that evaluated the safety and efficacy of rilpivirine compared to efavirenz in treatment-naïve HIV-infected adults. The pooled ECHO and THRIVE data demonstrated equal efficacy to the only other single-tablet regimen available but with an improved tolerability profile.

Both studies included a background regimen of two nucleosides/nucleotides, which for the majority of patients was TRUVADA.

Basic info

Generic name rilpivirine + tenofovir + emtricitabine
Brand name Eviplera
Also known as Complera in the United States
Drug class Fixed Dose Combinations
Pediatric dosing? Available in doses suitable for children and/or young people.
Availability in Australia Available on the Pharmaceutical Benefits Scheme (PBS) through S100 prescribers since 2012
This drug may be available through clinical trials in Australia.
You may be able to import this drug from overseas for your personal use.
Formulation 25 mg rilpivirine; 300mg tenofovir; 200mg emtricitabine

Taking it

Like most anti-HIV drugs, rilpivirine + tenofovir + emtricitabine must be taken in combination with other drugs to be completely effective. Commonly, rilpivirine + tenofovir + emtricitabine is combined with one other nucleoside (NRTI) drug and either a protease inhibitor or non-nucleoside, although other combinations are sometimes used. Your doctor will advise you on the right combination of drugs to suit your circumstances.


One tablet once a day

Regardless of what you read on this website or elsewhere, you should always take your medications according to your doctor's instructions. If you're unsure, speak to your doctor or pharmacist.

With or without food

rilpivirine + tenofovir + emtricitabine must be taken with a high-fat meal

Side effect

All drugs can produce side effects in some people. These may be mild, moderate or severe, so you should be aware of potential side effects before starting any drug, and speak to your doctor if you experience side effects that concern you.

  • Common side effects may include rash, insomnia, headaches.
  • Less common side effects may include depression, mood swings.
  • It's unlikely you will experience all of these side effects, and you may not experience any side effects at all. Before starting any new drug, ask your doctor about side effects you might experience and discuss strategies for dealing with side effects if they do occur. If you experience any significant side effect you should continue taking your medicine and see your doctor as soon as possible.

Interactions with other drugs

Nephrotoxic agents. Medicinal products that decrease or compete for renal clearance or compete with active tubular secretion. Didanosine (closely monitor for didanosine-associated adverse events). Atazanavir, atazanavir/ritonavir. QT prolonging drugs. Drugs inducing or Inhibiting CYP3A enzymes (see CONTRAINDICATIONS). Drugs Increasing Gastric pH (including proton pump inhibitors) (see CONTRAINDICATIONS). Potential interactions to take into consideration (no EVIPLERA dose adjustment required): darunavir/ritonavir, lopinavir/ritonavir, azole antifungal agents (ketoconazole), methadone (clinical monitoring and potential adjustment of methadone maintenance therapy). Meal planning required: famotidine and H2receptor antagonists.